Regenerex Pharma, INC
Market Movers (8-K)
Regenerex Pharma, Inc. has filed a lawsuit against its former Chief Financial Officer, Kenneth W. Perry, alleging fraud, embezzlement, and destruction of financial records.
Worse than expected
Delay expected
Regenerex Pharma, Inc. announced the termination of Chief Financial Officer Kenneth Perry for Cause, effective May 2, 2026, following a review of his conduct.
Regenerex Pharma suspends CFO Kenneth Perry pending review of financial oversight and governance concerns, appointing Don E. Ray as interim CFO.
Regenerex Pharma, Inc. announced a change in its fiscal year end from March 31 to December 31, effective September 22, 2025, to align with calendar year reporting.
Regenerex Pharma, Inc. has entered a binding agreement with Holista Colltech Ltd. for exclusive global rights to ovine collagen in advanced wound care.
Regenerex Pharma, Inc. has entered into a strategic licensing agreement with Holista Colltech Ltd. for exclusive rights to high-purity ovine collagen for wound care and U.S. distribution.
Better than expected
Quarterly Earnings (10-Q)
Regenerex Pharma reported a significantly increased net loss and substantial cash burn for the six months ended September 30, 2025, with zero revenue, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Delay expected
Regenerex Pharma, Inc. reported a significantly increased net loss of $663,584 for Q2 2025, with zero revenue and substantial doubt about its ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
Regenerex Pharma's Q3 2024 filing reveals a decreased net loss compared to the previous year, as the company continues to develop and market wound care products.
Worse than expected
Capital raise
Regenerex Pharma's Q2 2024 results show a decreased net loss compared to the same period last year, as the company continues to develop and market wound care products.
Worse than expected
Delay expected
Capital raise
Regenerex Pharma's Q1 2024 filing reveals a widening net loss and continued reliance on debt financing as the company prepares to launch its wound care products.
Worse than expected
Capital raise
10-Q: Regenerex Pharma Reports Increased Net Loss in Q3 2023 Amidst Intellectual Property Investments
Regenerex Pharma's Q3 2023 report reveals a significant increase in net loss due to intellectual property acquisition and increased operating expenses.
Worse than expected
Capital raise
Annual Reports (10-K)
Regenerex Pharma, Inc. reported a reduced net loss for the fiscal year ended March 31, 2025, driven by decreased research and development expenses, while actively pursuing significant strategic partnerships and additional capital to address ongoing liquidity challenges and a going concern doubt.
Delay expected
Capital raise
Worse than expected
Regenerex Pharma, a wound care company, reported its full year 2024 results, highlighting a significant net loss and ongoing efforts to launch its wound care products.
Capital raise
Worse than expected